Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
2023年11月15日 - 10:15PM
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage
biopharmaceutical company focused on developing small molecules to
restore neuronal health and slow neurodegeneration, presented new
preclinical data supporting the potential therapeutic benefit of
fosgonimeton for the treatment of Alzheimer’s disease (AD) and
other neurodegenerative diseases at the Society for Neuroscience
(SfN) Annual Meeting 2023, being held in Washington, D.C. from
November 11 – 15, 2023. Fosgonimeton is a potentially
first-in-class, small-molecule, brain-penetrant positive modulator
of the neurotrophic hepatocyte growth factor (HGF) system with the
potential to protect and repair neuronal networks.
“We continue to build the body of preclinical evidence
supporting the continued development of fosgonimeton to treat AD
and other debilitating neurodegenerative diseases,” said Kevin
Church, Ph.D., Chief Scientific Officer, Athira Pharma. “Our latest
data demonstrate consistent neuroprotective effects of fosgonimeton
and provide insights into the mechanisms by which it preserves
neurons from degeneration and reduces neuroinflammation. In vitro,
fosgonimeton protected neurons from toxic amyloid-beta (Aβ) and
decreased tau phosphorylation. In an Aβ model of AD in vivo,
fosgonimeton improved cognitive performance and reduced hippocampal
neuron loss. These data further support our approach of targeting
the neurotrophic HGF system in to treat AD and other
neurodegenerative diseases.”
Oral Presentation (#NAN076.02): Fosgonimeton, a
Small-Molecule Positive Modulator of the Neurotrophic HGF System,
Protects Against Amyloid beta-induced Pathological Alterations in
Alzheimer’s Disease Models In Vitro and In Vivo
Sharay Setti, Ph.D., Senior Scientist, Athira Pharma, presented
preclinical findings demonstrating fosgonimeton’s neurotrophic and
neuroprotective activity in Aβ models of AD.
- In vitro, the active metabolite of fosgonimeton reduced
Aβ-induced neurite degeneration, tau phosphorylation, mitochondrial
stress, and neuronal death.
- In an Aβ mouse model of AD, fosgonimeton improved cognitive
performance in both Y-maze and Morris water maze trials, protected
hippocampal neurons from degeneration, and promoted cell
proliferation in the subgranular zone, showing potential to support
adult neurogenesis.
Poster Presentation (#PSTR 203.06):
Fosgonimeton, a small-molecule positive modulator of the
neurotrophic hepatocyte growth factor system, inhibits LPS-mediated
neuroinflammation in BV2 microglia.
Wei Wu, Ph.D., Senior Scientist II, Athira Pharma, presented
preclinical research demonstrating the cellular mechanisms by which
fosgonimeton induces anti-inflammatory effects in BV2 microglia
cells.
- In vitro, the active metabolite of fosgonimeton inhibited the
expression of pro-inflammatory mediators, reduced mitochondrial
dysfunction, and decreased oxidative stress in LPS-stimulated
microglia.
- The anti-inflammatory effects of fosgonimeton demonstrated in
these models suggest it may have the potential to help reduce
neuroinflammation, a key pathological feature of several
neurodegenerative diseases.
The presentations are available on the Scientific Publications
& Presentations page of the company’s website
at www.athira.com.
About FosgonimetonFosgonimeton is a small
molecule designed to enhance the activity of the neurotrophic
hepatocyte growth factor signaling system, an endogenous repair
mechanism for a healthy nervous system. The function of the
neurotrophic HGF system may be impaired in conditions of
neurodegeneration. Targeting the protection and repair of neuronal
networks, fosgonimeton has disease-modifying potential to address a
broad range of neurodegenerative diseases, including Alzheimer’s
disease, Parkinson’s disease, and Dementia with Lewy bodies.
About Athira Pharma, Inc.Athira Pharma, Inc.,
headquartered in the Seattle, Washington area, is a late
clinical-stage biopharmaceutical company focused on developing
small molecules to restore neuronal health and slow
neurodegeneration. Athira aims to alter the course of neurological
diseases by advancing its pipeline of therapeutic candidates
targeting the neurotrophic HGF system for Alzheimer’s and
Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic
lateral sclerosis. For more information, visit www.athira.com.
You can also follow Athira on Facebook, LinkedIn, X (formerly known
as Twitter) and Instagram.
Forward-Looking StatementsThis communication
contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding: product
candidates as a potential treatment for Alzheimer’s disease,
Parkinson’s disease, Dementia with Lewy bodies, and other
neurodegenerative diseases, such as amyotrophic lateral sclerosis;
expectations regarding the potential efficacy and commercial
potential of Athira’s product candidates; and Athira’s ability to
advance its product candidates into later stages of development.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,” “on
track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,”
“continue,” “suggest,” “potential,” and other similar expressions,
among others. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the data from
preclinical and clinical trials may not support the safety,
efficacy and tolerability of Athira’s product candidates;
development of product candidates may cease or be delayed;
regulatory authorities could object to protocols, amendments and
other submissions; future potential regulatory milestones for
product candidates, including those related to current and planned
clinical studies, may be insufficient to support regulatory
submissions or approval; Athira may not be able to recruit
sufficient patients for its clinical trials; the outcome of legal
proceedings that have been or may in the future be instituted
against Athira, its directors and officers; possible negative
interactions of Athira's product candidates with other treatments;
Athira’s assumptions regarding the sufficiency of its cash, cash
equivalents and investments to fund its planned operations may be
incorrect; adverse conditions in the general domestic and global
economic markets; the impact of competition; regulatory agencies
may be delayed in reviewing, commenting on or approving any of
Athira’s clinical development plans as a result of pandemics or
health epidemics, which could further delay development timelines;
the impact of expanded product development and clinical activities
on operating expenses; the impact of new or changing laws and
regulations; as well as the other risks detailed in Athira’s
filings with the Securities and Exchange Commission from time to
time. These forward-looking statements speak only as of the date
hereof and Athira undertakes no obligation to update
forward-looking statements. Athira may not actually achieve the
plans, intentions, or expectations disclosed in its forward-looking
statements, and you should not place undue reliance on the
forward-looking statements.
Investor & Media ContactJulie RathbunAthira
PharmaJulie.rathbun@athira.com 206-769-9219
Athira Pharma (NASDAQ:ATHA)
過去 株価チャート
から 5 2024 まで 6 2024
Athira Pharma (NASDAQ:ATHA)
過去 株価チャート
から 6 2023 まで 6 2024